samedan logo
 
 
 
spacer
home > ebr > spring 2018 > getting ahead
PUBLICATIONS
European Biopharmaceutical Review

Getting Ahead

Migraine is not a new or a rare disease: references to migrainelike conditions can be found as far back as Ancient Egypt, and it has been recognised by the WHO as one of the top 10 causes of years lost to disability worldwide (1-2). Despite this, migraine patients in need of a preventive option are likely to be prescribed a medication that has been developed for another condition such as epilepsy or depression, rather than something that was designed with migraine in mind. However, there is hope that this will soon change.

Pathophysiology of Migraine

The understanding of the pathophysiology of migraine has advanced hugely over the past two decades. While in the past theories of migraine focused on the vascular system, research has moved away from this towards a neuronal theory of migraine (3). However, the role of blood vessels and vasodilation is still not entirely understood.

Migraine is a complex neurological disease of the central nervous system (CNS), with several structures and brain areas implicated in its genesis. A key focus area has been the trigeminovascular system. This has connections with other key brain areas with axons reaching as far as the meninges. Activation of this system is thought to be a crucial step in a chain of events leading to migraine pain.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Professor Dr Uwe Reuter is a neurologist and partner in the headache programme at Charité Universitätsmedizin, Berlin. After finishing his residency training in Berlin, he went to Harvard Medical School for a post-doctorate fellowship as a scholar for three years. During his time in Boston, Uwe focused on basic research in primary headaches and migraine aura and published several peer-reviewed publications in high impact journals. Ever since, he has had a strong interest in basic and clinical headache research. Uwe is a member of several national and international headache organisations and currently serves as board member of the European Headache Federation.
spacer
Professor Dr Uwe Reuter
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Bormioli Pharma runs Envision 2020: A Digital Event to Showcase The New Strategic Directions, Brand-New Product Portfolios and Prototypes

Parma, 24 November 2020 – Bormioli Pharma will showcase its brand-new product portfolios, products and prototypes during “Bormioli Pharma Envision 2020”, a digital event that will take place in the first half of December open to all the stakeholders. The event will be the occasion to get in touch with the leading European pharma packaging manufacturer in glass and plastic in such hectic times for the industry. Even during the Covid-19 pandemic, the company has kept the momentum for its expansion and growth process, finalizing new investments and M&As to enlarge its industrial platform and the products range.
More info >>

White Papers

The Rare Disease Patients Experience

When planning a clinical trial for a rare disease, it is important to have a holistic understanding of your patient population. You want to be aware of where your patients are coming from, and what it is like to walk in their shoes. These patients need your trial just as much as you need them; even from the earliest stages, conceptualize your rare disease trial as an altruistic relationship between the patient population and your study.
More info >>

 
Industry Events

12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

8-11 February 2021, Vienna, Austria

In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 8-11 Feb 2021. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement